The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Clinical parameters, including tear meniscus height, tear break up time (TBUT), conjunctival hyperemia, and Ocular Surface Disease Index (OSDI) scores, were assessed and correlated with changes in the ...